Lexaria BioscienceLEXX
LEXX logo
Fair Value
US$5.55
Share price26 Jan
US$0.5689.9% undervalued intrinsic discount
Loading
1Y-36.02%
7D-1.62%

Lexaria Bioscience's Breakthrough with DehydraTECH to Revolutionize Drug Delivery

Author hasn't set their bio yet

Published
26 Jan 26
Views
202
Not Invested

Fair Value vs Share Price

US$5.55
vs US$0.5689.9% undervalued intrinsic discount
PastFuture-9m204m20152018202120242026202720302031Revenue US$203.6mEarnings US$31.1m
229.8%
Revenue growth
15.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Lexaria Bioscience

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Medium-low risk with adequate balance sheet.

Market capUS$13.9m
PB2.1x
Estimated Growth73.9%
Dividend YieldN/A
Full analysis

CEO & management

Richard Christopher
CEO
1.8yrs
CEO Tenure

Operates as a biotechnology company.